Drugs / ATx201
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03375957 | Jan → Feb 2018 | — | UNION therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03301870 | Oct → Nov 2017 | — | UNION therapeutics | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03009734 | Dec 2016 → Mar 2018 | bacterial infectious disease | UNION therapeutics | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT04339985 | Oct 2019 → Oct 2020 | atopic eczema | UNION therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03429595 | Feb → Jun 2018 | impetigo | UNION therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03304470 | Sep 2017 → Mar 2018 | atopic eczema | UNION therapeutics | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ATx201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03429595 ↗ |
| Route | Topical | “Topical application of ATx201 dermal formulations 2%” NCT03009734 ↗ |